- At #SNMMI24, GE HealthCare expands its technology with the
addition of a MINItrace Magni,i designed to be a small
footprint cyclotron for reliable, in-house production of commercial
PET tracers and radiometals; Omni Legend 21 cm, ii a
performance-focused PET/CT designed to evolve and help meet growing
healthcare system demands across care areas; and Clarify
DL,iii a new deep learning reconstruction technology designed
to deliver clear, accurate, and effortless imaging
- Combined with GE HealthCare’s well-established portfolio –
including portable systems to reach remote populations and
refurbished medical equipment to help improve access to affordable,
quality healthcare – these technologies and the Company’s recently
acquired MIM Software solutions aim to expand global access to
precision care
GE HealthCare once again joins the world’s top medical and
academic institutions at the Society of Nuclear Medicine and
Molecular Imaging (SNMMI) annual meeting to discuss today’s
healthcare landscape and announce new precision care tools to meet
providers’ most pressing needs – namely the accessibility of
technologies and solutions for the global practice of personalized
medicine.
More than half of the world’s population is underserved and
lacks access to essential health services,iv and two-thirds have no
access to diagnostic imaging.v Yet even those who have these
services and systems within reach may struggle to receive necessary
scans due to the challenges healthcare providers often face in
reliably sourcing commercial PET tracers – leaving many patients
and medical centers around the world without recourse. These
shortfalls, in addition to ongoing healthcare resource and staff
shortages,vi challenge the adoption of precision care globally.
“It’s not enough to develop cutting-edge solutions if they
aren’t also made more accessible to clinicians and patients around
the world,” shares Jean-Luc Procaccini, President & CEO,
Molecular Imaging & Computed Tomography, GE HealthCare. “While
there is still much work to be done, we are proud to offer a
variety of technologies that can evolve with healthcare system
needs and help support a patient’s entire care journey – from the
systems required to create the radiotracers used to diagnose and
monitor disease, to the imaging equipment used for a noninvasive
look at a patient’s anatomy and treatment monitoring, to the
software optimized to measure lesion size and dose. In the hands of
clinicians, these tools help make the practice of precision care
more accessible and aim to help improve patient outcomes
globally.”
As clinicians seek to practice more personalized medicine –
including Theranostics, a type of precision care that combines
diagnostics and therapy – they increasingly look to leverage
imaging techniques that more accurately inform diagnoses and
measure functional and molecular responses to therapy.
Increasing access to better support patient care
GE HealthCare aims to design and develop a range of products
that support these efforts, empowering global healthcare providers
to address the needs of all patient populations.
For the practice of precision care in molecular imaging and
nuclear medicine, this begins with the production of radioisotopes
for use in diagnostic tracers, which are administered to patients,
attach to specific biomarkers, and release radioactive emissions to
provide clinicians detailed molecular information unique to each
patient.
However, as the positive and exponential rise of Theranostics
drives greater demand for these radioisotopes (or tracers), the
limitations of traditionally used generators have created serious
challenges for clinicians and limited patient access.
In response, GE HealthCare is proud to announce the development
of its new MINItrace Magni,i designed to be a small
footprint, cost effective cyclotron for reliable, in-house
production of commercial PET tracers and radiometals – like
Gallium-68 – through solid target technology. When produced in
combination with the company’s TRACERcenter – which is designed to
serve as a complete PET radiopharmacy solution – the resulting
radiopharmaceuticals can help physicians identify and diagnose
clinical signs across care areas – including oncology, cardiology,
and neurology.vii
Adoption of such easy-to-site, easy-to-install technology may
help enhance the capabilities of the healthcare system, but also
grant clinicians the ability to offer a variety of tracers to their
patients and encourage the practice of precision care locally,
helping fuel inhouse Theranostics capabilities.
GE HealthCare also designs its systems with accessibility and
longevity in mind, recognizing that once a system is acquired for a
community, it will be depended on for many years to come.
To this end, GE HealthCare is excited to broaden its Omni
platform with Omni Legend 21 cm,ii a performance-focused
PET/CT that is designed to evolve and help meet growing healthcare
system demands across care areas, including: striking image quality
in oncology; an ability to accommodate increasing PET amyloid
imaging volume related to Alzheimer's diagnosis in neurology; and
impressive imaging of a variety of cardiac tracers, including fast
decay tracers and new tracers in cardiology.
These abilities are supported by the system’s innovative 21 cm
digital detector designed for augmented NEMA sensitivity,viii in
combination with deep learning reconstruction capabilities,
advanced digital solutions, and enhanced workflow offerings powered
by AI. As a result, Omni Legend is designed to enable clinicians
reduce the dose by up to 40%ix while maintaining exceptional image
quality. Effortless Workflow, an AI based patient Auto Positioning
solution, also helps address operational and staffing shortage
challenges.
Additionally, the Omni platform is scalable, allowing radiology
departments and healthcare facilities to upgrade the hardware and
add service lines to help meet growing demand as well as optimize
clinical capabilities, ensure access to the latest technology, and
accommodate evolving community needs for many years to come.
GE HealthCare also offers Omni Legend mobile, an
all-in-one portable PET/CT solution that makes the company’s
impressive Omni Legend system available to regional or local scan
centers and hospitals, helping increase access and reduce the
amount of travel required for more vulnerable or remote patient
communities.
Software as an enabler of precision care
Ultimately, achieving a more personalized and flexible
healthcare experience requires fundamental changes in the way
healthcare operates. The system must evolve to be smarter, easier,
and more collaborative.
Fortunately, the rise and development of digital and artificial
intelligence (AI) solutions makes new tools available to clinicians
in the practice of precision medicine.
Revealed for the first time at #SNMMI24, Clarify DLiii
represents a new deep-learning reconstruction technology trained on
bone SPECT images to establish a network designed to reduce noise
while maintaining contrast. The result is an AI-powered solution
designed to deliver clear, accurate, and effortless imaging – a
stark contrast to today’s noise reduction techniques, which
typically lower contrast and resolution and may impact accuracy and
diagnostic confidence.
The new AI-based solution is designed for GE HealthCare’s
cutting-edge StarGuide digital SPECT/CT. The system’s 12 CZT
detector design not only scans patients in 3D to provide more
information to clinicians but is also optimized for certain
theragnostic procedures, which in turn helps clinicians pinpoint
the size, shape, and position of lesions with exceptional accuracy.
It also helps clinicians evaluate the success of therapies and need
for treatment follow up.
StarGuide also offers several additional innovations, such as
flexibility in patient scanning, workflow efficiencies that help
reduce complexities and processing time in Theranostics as well as
scanning protocols, such as Dynamic SPECT imaging.
“Theranostics is awesome – it’s a life extender,” shares Doug, a
Theranostics patient scanned on BAMF Health’s StarGuide system.
“This is nothing short of a miracle. I can’t believe we’re seeing
this in our lifetime.”
In the spirit of advancing Theranostics and providing clinicians
additional digital solutions to help improve patient outcomes, GE
HealthCare recently acquired MIM Software with the aim of
delivering innovative digital solutions – including MIM Encore and
MIM SurePlan MRT– across care pathways for precise, connected, and
efficient care across disease states. Collectively, MIM Software’s
full portfolio of vendor neutral solutions offers clinicians
workflow automation and flexible configuration options for
excellent flexibility, automation, and efficiency. This includes
streamlined processing, structured reporting, fast and high-quality
contouring, advanced image fusion, dosimetry capabilities, easy IT
integration, and remote access – helping to boost healthcare
productivity and promote personalized patient care.
Product life extension & upgrades
GE HealthCare is also proud to offer global refurbished medical
equipment, helping to improve access to affordable, quality
healthcare. High-quality refurbished medical equipment is a viable
diagnostic imaging option for hospitals seeking to stretch their
budgets by purchasing used, but still exceptionally good,
systems.
Additionally, with technology advancements and software
upgrades, the lifespan of equipment can be extended and enhanced to
help improve clinical outcomes.
Today’s healthcare access challenges demand creative solutions
to solve complex problems. At GE HealthCare, the answer is new and
modular systems, innovative digital and AI solutions, and
refurbished equipment – all in the pursuit of increasing access to
and the practice of precision care for earlier, more precise, and
accessible diagnosis and treatment of patients around the
world.
For more information on GE HealthCare’s Molecular Imaging and
MIM Software solutions, please visit gehealthcare.com and
mimsoftware.com. GE HealthCare will also showcase these
technologies and solutions at the Society of Nuclear Medicine and
Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto,
Canada.
Earlier this week, GE HealthCare also announced that in its
sponsored pharmaco-economic study, published in peer-reviewed
journal PLOS ONE, the incidence, prevalence, diagnostic pathways,
and treatments of different patients with metastatic or recurrent
breast cancer were analyzed using a combination of widely accepted
statistical modelling methods to estimate the clinical and
associated economic impact of adding a PET/CT scan with a breast
oncology PET tracer to the current standard diagnostic process. The
study shows that adding a PET/CT scan with a breast oncology PET
tracer may increase the accuracy of knowing the estrogen receptor
(ER) status, and increased accuracy may help clinicians select more
effective treatments and decrease the rate of re-biopsies,
resulting in the potential cost savings of $142M to the US
healthcare system over a five-year period. Click here to learn
more.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), Facebook,
Instagram, and Insights for the latest news, or visit our website
https://www.gehealthcare.com/ for more information.
i Technology in development that represents ongoing research and
development efforts. These technologies are not products and may
never become products. Not CE marked. ii Omni Legend 21cm is CE
marked. Not approved or cleared by U.S. FDA. Not licensed in
accordance with Canadian law. Not available for sale in the United
States and Canada. Not commercially available in all markets. iii
Clarify DL is 510(k)-pending with the U.S. FDA. Not licensed in
accordance with Canadian law. Not available for sale in the United
States and Canada. Not commercially available in all markets. iv
World Health Organization, World Bank Group. Tracking universal
health coverage: 2023 global monitoring report. Sep 2023.
https://www.who.int/publications/i/item/9789240080379 v An audit of
licensed Zimbabwean radiology equipment resources as a measure of
healthcare access and equity - PMC (nih.gov) vi World Health
Organization Secretariat. Global strategy on human resources for
health: Workforce 2030. Geneva: WHO. 2016. Available from:
https://apps.who.int/iris/bitstream/handle/10665/250368/9789241511131-eng.pdf.
Accessed: April 27, 2022. vii MINItrace Magni is designed to
produce the following radionuclides for use across care areas: F,
11C, 13N, 15O, 68Ga, 89Zr, 61/64Cu and more. viii Omni Legend 21 cm
has up to a 1.6x increase in system sensitivity as compared to
Discovery MI Gen1 20 cm. Measurements follow NEMA NU 2-2018. ix
Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As
demonstrated in phantom testing.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240607297244/en/
GE HealthCare media contact Margaret Steinhafel Global
Communications Director Molecular Imaging & Computed Tomography
M +1 608 381 8829 margaret.steinhafel@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From May 2024 to Jun 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Jun 2023 to Jun 2024